The Medigene Share
The Medigene share MDG1 (ISIN:DE000A1X3W00 ) is listed at the Frankfurt Stock Exchange since June 2000.
Investors & Media
Welcome to the Investor Relations and Public Relations division of Medigene AG. This is where you will find current information on a variety of subjects, including Medigene AG shares, company news, financial reports and key figures.
Latest News
New safety data shows Medigene's inducible system produces correctly-paired T cell receptors only
Medigene, IRICoR, and University of Montréal expand analyses of potentially novel cancer antigens
Events
22 - 24
Feb 2022
Next Generation CAR-TCR Summit
23
Mar 2022
Annual Report 2021
04
May 2022
Quarterly Statement Q1 2022
18
May 2022
Annual General Meeting 2022
03
Aug 2022
6-Months Report 2022
07 - 08
Sep 2022
Stifel London Cross Sector Insight Conference
02
Nov 2022
Quarterly Statement Q3 2022
Corporate Governance
Good corporate governance is the basis of our decision-making and monitoring processes. It stands for responsible and value-based leadership and control of the Company for long-term success, goal-oriented and efficient cooperation between the Executive Board and Supervisory Board, respect for the interests of our shareholders and employees, consistently transparent and responsible corporate decisions and an appropriate risk management system.
Contact person
Dr. Anna Niedl
Vice President Investor Relations & Corporate Communications
investor(at)medigene.com
Phone: +49 89 2000 3333 01
Fax: +49 89 2000 33 2920